TY - JOUR AU - Wu, Jia-Wei AU - Hu, Hao AU - Li, Dan AU - Ma, Li-Kun PY - 2019 TI - In-hospital outcomes of delayed stenting in hemodynamically stable patients with ST-segment elevation myocardial infarction: the CCC (Care for Cardiovascular Disease in China) project JF - Cardiovascular Diagnosis and Therapy; Vol 9, No 5 (October 22, 2019): Cardiovascular Diagnosis and Therapy Y2 - 2019 KW - N2 - Background: For hemodynamically stable patients with ST-segment elevation myocardial infarction (STEMI) who missed the reperfusion window, optimal timing for delayed revascularization remains controversial. Methods: We investigated 7,698 consecutive patients without cardiogenic shock, serious heart failure, or thrombolysis who underwent delayed stenting (12 hours to 28 days after STEMI) at multiple centers in China. The patients were divided according to delayed PCI timing into very early (12–72 hours), early (3–7 days), intermediate (7–14 days) and late (14–28 days) groups. The primary outcome was in-hospital rate of major adverse cardiovascular events (MACE); secondary outcomes were in-hospital rates of all bleeding events, heart failure and sudden cardiac arrest (SCA). All endpoint events were a composite of the primary and secondary endpoints. Results: In-hospital MACE rate was similar among groups (P=0.588). Patients who underwent late vs . very early, early and intermediate delayed PCI had higher in-hospital rates of secondary events (13% vs . 8.0%, 8.1% and 0.3%, P vs . 6.2%, 6.3% and 7.6%, P vs . intermediate group was at higher risk (OR =1.26, 95% CI: 1.02 to 1.56, P=0.029); and in subgroup analysis, patients with Killip class II or III heart failure had similar rates (OR =1.02, 95% CI: 0.74 to 1.40, P=0.908); while women (OR =1.67, 95% CI: 1.07 to 2.62, P=0.024), and smokers (OR =1.46, 95% CI: 1.05 to 2.02, P=0.023) had higher rates. Conclusions: Late delayed PCI (14–28 days) after STEMI was associated with a higher incidence of in-hospital adverse events particularly in women and smokers but not with Killip class II–III heart failure, which might allow medical treatment to improve function. UR - https://cdt.amegroups.org/article/view/30056